Bariatric surgery for diabetes management

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 16, Issue 2, 2009, Pages 119-124

  Frachetti, Katherine J ^a,b   Goldfine, Allison B ^b,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c JOSLIN DIABETES CENTER   (United States)

Author keywords

Bariatric surgery; Obesity; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; DIAZOXIDE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; LEPTIN; PEPTIDE YY; SOMATOSTATIN DERIVATIVE; TRACE ELEMENT; HORMONE;

BACTERIAL ARTHRITIS; BARIATRIC SURGERY; BODY MASS; CARDIOMYOPATHY; CLINICAL TRIAL; COMORBIDITY; CYANOCOBALAMIN DEFICIENCY; DIABETIC OBESITY; DIABETIC PATIENT; DISEASE DURATION; DYSLIPIDEMIA; ENTERITIS; GASTRIC BANDING; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROPLASTY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERINSULINEMIC HYPOGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN HYPOGLYCEMIA; JEJUNOILEAL BYPASS; LIFESTYLE MODIFICATION; LIVER FAILURE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DEFICIENCY; OBESITY; OBESITY HYPOVENTILATION SYNDROME; OSTEOPENIA; OSTEOPOROSIS; POSTGASTRECTOMY SYNDROME; PROTEIN MALNUTRITION; REMISSION; REOPERATION; REVIEW; ROUX Y ANASTOMOSIS; SLEEP APNEA SYNDROME; SPLEEN INJURY; STOMACH BYPASS; STONE FORMATION; SURGICAL APPROACH; SURGICAL MORTALITY; SURGICAL RISK; SURGICAL WOUND; SURVIVAL TIME; VITAMIN D DEFICIENCY; VITAMIN DEFICIENCY; WEIGHT CONTROL; WEIGHT REDUCTION; BLOOD; HYPERINSULINISM; METABOLISM; MORTALITY; PHYSIOLOGY;

BARIATRIC SURGERY; DIABETES MELLITUS, TYPE 2; DUMPING SYNDROME; HORMONES; HUMANS; HYPERINSULINISM; HYPOGLYCEMIA; MICRONUTRIENTS; OBESITY; WEIGHT LOSS;

EID: 66149113356     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32832912e7     Document Type: Review

References (41)

1. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295:1549-1555.
2. Overweight, obesity, and health risk. National Task Force on the Prevention and Treatment of Obesity. Arch Intern Med 2000; 160:898-904.
3. Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341:1097-1105.
4. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357:741-752. This article is a case-controlled study of a large patient cohort demonstrating sustained benefits, including improved survival for patients following bariatric surgery.
5. Knowler WC, Barrett-Connor E, Fowler SE, et al., Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.
6. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20:537-544.
7. Eriksson KF, Lindgarde F. Prevention of type 2 (noninsulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 1991; 34:891-898.
8. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292:1724-1737.
9. Williamson DF, Thompson TJ, Thun M, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23:1499-1504.
10. Wing RR, Koeske R, Epstein LH, et al. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147:1749-1753.
11. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351:2683-2693.
12. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003; 238:467-484; discussion 484-465.
13. Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008; 299:316-323. This is a carefully performed randomized control trial of laproscopic band compared with optimal medical control in adults with type 2 diabetes, with 2-year outcome data. Furthermore, to date, it is the only randomized trial comparing surgical with medical approaches.
14. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357:753-761. This is a well performed population-based outcome study comparing bariatric surgery with standard care. This study supports improved survival, especially for patients with diabetes.
15. Rubino F. Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care 2008; 31 (Suppl 2):S290-S296.
16. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med 1991; 115:956-961.
17. Mun EC, Blackburn GL, Matthews JB. Current status of medical and surgical therapy for obesity. Gastroenterology 2001; 120:669-681.
18. Santry HP, Gillen DL, Lauderdale DS. Trends in bariatric surgical procedures. JAMA 2005; 294:1909-1917.
19. Encinosa WE, Bernard DM, Steiner CA, Chen CC. Use and costs of bariatric surgery and prescription weight-loss medications. Health Aff (Millwood) 2005; 24:1039-1046.
20. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after dietinduced weight loss or gastric bypass surgery. N Engl J Med 2002; 346:1623-1630.
21. Hanusch-Enserer U, Cauza E, Brabant G, et al. Plasma ghrelin in obesity before and after weight loss after laparoscopical adjustable gastric banding. J Clin Endocrinol Metab 2004; 89:3352-3358.
22. Morinigo R, Moize V, Musri M, et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2006; 91:1735-1740.
23. Borg CM, le Roux CW, Ghatei MA, et al. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg 2006; 93:210-215.
24. Faraj M, Havel PJ, Phelis S, et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003; 88:1594-1602.
25. Zingmond DS, McGory ML, Ko CY. Hospitalization before and after gastric bypass surgery. JAMA 2005; 294:1918-1924.
26. Flum DR, Salem L, Elrod JA, et al. Early mortality among Medicare bene-ficiaries undergoing bariatric surgical procedures. JAMA 2005; 294:1903-1908.
27. Flum DR, Dellinger EP. Impact of gastric bypass operation on survival: a population-based analysis. J Am Coll Surg 2004; 199:543-551.
28. Brolin RE. Bariatric surgery and long-term control of morbid obesity. JAMA 2002; 288:2793-2796.
29. Christou NV, Sampalis JS, Liberman M, et al. Surgery decreases long-term mortality, morbidity, and healthcare use in morbidly obese patients. Ann Surg 2004; 240:416-423; discussion 423-414.
30. Gebhard B, Holst JJ, Biegelmayer C, Miholic J. Postprandial GLP-1, norepinephrine, and reactive hypoglycemia in dumping syndrome. Dig Dis Sci 2001; 46:1915-1923.
31. Ukleja A. Dumping syndrome: pathophysiology and treatment. Nutr Clin Pract 2005; 20:517-525.
32. Brolin RE, Gorman JH, Gorman RC, et al. Are vitamin B12 and folate deficiency clinically important after roux-en-Y gastric bypass? J Gastrointest Surg 1998; 2:436-442.
33. Gasteyger C, Suter M, Gaillard RC, Giusti V. Nutritional deficiencies after Roux-en-Y gastric bypass for morbid obesity often cannot be prevented by standard multivitamin supplementation. Am J Clin Nutr 2008; 87:1128-1133. This study points out specific nutritional risks for patients who have had gastric bypass procedures.
34. Clements RH, Katasani VG, Palepu R, et al. Incidence of vitamin deficiency after laparoscopic Roux-en-Y gastric bypass in a university hospital setting. Am Surg 2006; 72:1196-1202; discussion 1203-1194.
35. Johnson JM, Maher JW, DeMaria EJ, et al. The long-term effects of gastric bypass on vitamin D metabolism. Ann Surg 2006; 243:701-704; discussion 704-705.
36. Clements RH, Yellumahanthi K, Wesley M, et al. Hyperparathyroidism and vitamin D deficiency after laparoscopic gastric bypass. Am Surg 2008; 74:469-474; discussion 474-465. Vitamin D deficiency is increasingly recognized to occur in patients with bariatric procedures. This study demonstrates that it may also occur with restrictive procedures.
37. Goldfine AB, Mun E, Patti ME. Hyperinsulinemic hypoglycemia following gastric bypass surgery for obesity. Curr Opin Endocrinol Diabetes 2006; 13:419-424.
38. Service GJ, Thompson GB, Service FJ, et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005; 353:249-254.
39. Patti ME, McMahon G, Mun EC, et al. Severe hypoglycaemia postgastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 2005; 48:2236-2240.
40. Goldfine AB, Mun EC, Devine E, et al. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab 2007; 92:4678-4685. Patients who present with neuroglycopenia following RNYGB surgery are compared with patients without symptomatic hypoglycemia.
41. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002; 143:4397-4408.